Symbols

ELUT

Elutia·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ELUT

Elutia Inc.

A commercial-stage regenerative medicine company that develops regenerative medical products for patients undergoing surgery and receives implantable devices

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

10/08/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.elutia.com

Security Type

Common stock

Office address

20 Firstfield Road Gaithersburg MD 20878

Business

Introduction

Elutia Inc., was incorporated in Delaware in August 2015. The company develops proprietary drug-eluting biological matrix products for surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. The company's focus is on addressing unmet medical needs and reducing surgery-related complications, including infection, migration, erosion, implant rejection and fibrosis. The company operates across R&D through the commercial distribution of bio-matrix products for plastic and reconstructive surgery.

Company Financials

EPS

ELUT has released its 2025 Q4 earnings. EPS was reported at 1.48, versus the expected -0.12, beating expectations. The chart below visualizes how ELUT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ELUT has released its 2025 Q4 earnings report, with revenue of 3.27M, reflecting a YoY change of 16.16%, and net profit of 70.79M, showing a YoY change of 881.27%. The Sankey diagram below clearly presents ELUT's revenue sources and cost distribution.